

Genentech, Inc.

1 DNA WAY
South San Francisco, CA 94080
(650) 225-1000
Facsimile: (650) 952-9881

FACSIMILE TRANSMITTAL

RECEIVED
CENTRAL FAX CENTER

DATE: September 23, 2005

SEP 23 2005

Please deliver the following page(s) to:

NAME: Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Fax No.: (571) 273-8300

FROM: Wendy M. Lee
Registration No.: 40,378

RE: U.S. Serial No.: 10/719,310
Our Docket No.: P1979R1

Number of Pages including this cover sheet - 3

CERTIFICATION OF FACSIMILE TRANSMISSION UNDER 37 CFR § 1.8	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
<u>Wendy M. Lee</u> Type or print name of person signing certification	
Signature <u>Wendy M. Lee</u>	Date: <u>9-23-05</u>

CONFIDENTIAL NOTE

The documents accompanying this facsimile transmission contain information from GENENTECH, INC. which is confidential or privileged. The information is intended only for the individual or entity named on this transmission sheet. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this faxed information is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the original documents to us and the retransmission of them to the intended recipient.

If you do not receive all pages, please notify Wendy M. Lee at (650) 225-1994.


Enclosed for consideration and entry on the record in connection with the above application are: this cover page and Restriction Requirement Response.

RECEIVED
CENTRAL FAX CENTER

SEP 23 2005

Patent Docket P1979R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Paul G. Brunetta et al. Serial No.: 10/719,310 Filed: November 21, 2003 For: THERAPY OF NON-MALIGNANT DISEASES OR DISORDERS WITH ANTI-ERBB2 ANTIBODIES	Group Art Unit: 1644 Examiner: Phuong N Huynh Confirmation No. 3292 Customer No. 09157 Certificate of Facsimile Transmission Under 37 CFR § 1.9 In accordance with CFR § 1.6(d), this correspondence addressed to Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450 is being transmitted to facsimile No. (571) 273-6300 September 23, 2005  Wendy M. Lee
---	---

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is responsive to the restriction requirement mailed 8/26/2005.

On pages 2-3 of the restriction requirement, the Examiner has called for restriction to one of the inventions of Groups 1 to 8. Applicants elect the Group 1 invention, drawn to therapy of psoriasis. Applicants request that Group 1 claims (claims 19, and 29-32) be examined together with linking claims (claims 1-18).

In the paragraph spanning pages 4-5 of the restriction requirement, the Examiner has further requested that applicant elect a species from (1) a specific second therapeutic agent such as the ones recited in claims 15 and 32, and (2) whether the antibody is conjugated or not conjugated with a cytotoxic agent as set forth in claims 12-14. As to (1), Applicants elect the species of an "immunosuppressive agent." Group 1 and linking claims readable on this first elected species include: claims 1-19 and 29-32. In respect of (2), Applicants elect the species "wherein the antibody is not conjugated with a cytotoxic agent." Group 1 and linking claims readable on this second elected species include: claims 1-13, 15-19, and 29-32.

Prosecution on the merits is awaited.

Serial No.: 10/719,310

Respectfully submitted,
GENENTECH, INC.

Date: September 23, 2005

By: 

Wendy M. Lee

Reg. No. 40,378

Telephone: (650) 225-1994